A clinical trial led by Niels Rahe-Meyer at Franziskus Hospital in Germany found that a new human fibrinogen concentrate (FC) effectively reduced surgical blood loss and improved safety in patients undergoing major spinal or abdominal surgeries compared to traditional blood products like fresh frozen plasma (FFP) and cryoprecipitate (Cryo). Involving 222 patients across 15 hospitals in Europe and the UK, the study reported a significant reduction in mean intraoperative blood loss and quicker achievement of target fibrinogen levels, suggesting FC as a viable first-line option for managing fibrinogen deficiency during high-risk surgeries.

Source: eClinicalMedicine